LexaGene Retains Wolf Greenfield Intellectual Property Law Firm
Announces participation in national investor conference and webcast on Thursday, July 15
BEVERLY, Mass., July 14, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops a fully automated rapid pathogen detection system, today announced its strategic relationship with Wolf Greenfield, an intellectual property (IP) law firm, specializing in patents, licensing and royalty transactions, post-grant proceedings, and trademark and copyrights.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated, “As LexaGene continues to grow, it’s important to not only protect but nurture and grow the intellectual property assets of the Company. I’m very pleased to have the nationally recognized expertise of Wolf Greenfield on board for all of our strategic IP and licensing needs moving forward.”
“The addition of Wolf Greenfield to our team will be important as we continue expand our patent portfolio,” continued Dr. Regan. “And combining the strengths of Wolf Greenfield for IP law and licensing, along with Latham & Watkins for securities law, gives us the capabilities of two of the most respected law firms in the U.S. in their respective fields, as we continue to execute on our growth objectives.”
Adding Wolf Greenfield to its representation portfolio strengthens LexaGene’s positioning towards possibly listing its common shares on the Nasdaq Capital Market.
The Company also announced that Dr. Regan will be speaking at the “Access to Giving” investor conference on Thursday, July 15. Access to Giving is a first-of-its-kind, virtual investor conference, where companies from microcap up to mega-cap will have the opportunity to present their company’s vision and participate in meetings with qualified investors, all to benefit a range of charities. To register or to learn more visit, https://www.accesstogiving.com/. To listen to LexaGene’s presentation register here: https://www.webcaster4.com/Webcast/Page/2744/41999. The audio recording will be posted to the LexaGene website, at a later date.
To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit www.lexagene.com, or follow us on Twitter or LinkedIn.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
About Wolf Greenfield
For nearly a century, Wolf Greenfield has helped its clients protect their most valuable intellectual property. With over 150 legal professionals based in Boston and New York, the firm offers a full range of IP services, including patent prosecution and litigation; post-grant proceedings, including IPRs; opinions and strategic counseling; licensing; intellectual property audits and due diligence; trademark and copyright prosecution and litigation; and other issues related to the commercialization of intellectual property.
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing, and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go.’ The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Corporate Contact: Gail Winslow Director of Corporate Marketing gwinslow@lexagene.com 978.482.6237 ir@lexagene.com 800.215.1824
